

--RELATED APPLICATIONS

This application claims priority from European Patent Application No. 03075001.2, filed on January 2, 2003; which is hereby incorporated herein by reference.--

IN THE CLAIMS

1. (Original) A biocompatible polymer composition, suitable for *in vivo* vessel repair, comprising a matrix pre-polymer, a filler and a curing agent, wherein said composition has a viscosity of 2 000 to 12 000 cSt at 25 °C and wherein said biocompatible polymer composition is curable in the presence of a curing catalyst at 37 °C to form a cured material with an elongation until rupture of at least 5 % and an elastic modulus of at least 1 MPa.
2. (Original) Composition according to claim 1, wherein the viscosity of the biocompatible polymer composition is in the range of 3 000 to 10 000 cSt, preferably of 4 000 to 8 000 cSt.
3. (Currently Amended) Composition according to claim 1-~~or~~2, wherein said biocompatible polymer composition is curable in the presence of a curing catalyst at 37 °C to form a cured material with an elongation until rupture of at least 10 %, preferably at least 25 %.
4. (Currently Amended) Composition according to ~~any of the preceding claims~~ 1, wherein the matrix pre-polymer is a silicon (pre-)polymer, preferably a polydialkylsiloxane (pre-)polymer comprising at least two vinyl groups more preferably, more preferably polydialkylsiloxane (pre-)polymer comprising three to five vinyl groups.
5. (Currently Amended) Composition according to ~~any of the preceding claims~~ 1, wherein the filler is a hydrophobic filler.

6. (Currently Amended) Composition according claim ~~5~~1, wherein the hydrophobic filler is modified with an organosilicon compound, preferably with a vinylalkylsiloxane.
7. (Currently Amended) Composition according to ~~any of the preceding claims~~ 1, wherein the biocompatible polymer composition comprises a curing-inhibitor.
8. (Currently Amended) Composition according to ~~any of the preceding claims~~ 1, wherein the concentration of the matrix pre-polymer is 10 to 85 wt. % based on the total weight of the composition, preferably 50-70 wt. %.
9. (Currently Amended) Composition according to ~~any of the preceding claims~~ 1, wherein the curing agent is present in an amount of at least 0.1 wt. % based on the total weight of the composition.
10. (Currently Amended) Composition according to ~~any of the preceding claims~~ 1, wherein the curing agent is a polyalkylhydrosiloxane polymer, preferably a polyalkylhydrosiloxane copolymer comprising alkylhydrosiloxane moieties and dialkylsiloxane moieties, more preferably comprising methylhydrosiloxane moieties and dimethylsiloxane moieties.
11. (Currently Amended) Composition according to ~~any of the preceding claims~~ 1, wherein the curing agent is present in an amount providing a number of functional groups in the range of 1-10 times the number of functional groups that is provided by the matrix pre-polymer.
12. (Currently Amended) Composition according to ~~any of the preceding claims~~ 1, - wherein the filler is present in an amount of 1-50 wt. %, preferably 2-45 wt. %, more preferably 15-40 wt. %, based on the total weight of the composition.

13. (Currently Amended) Composition according to ~~any of the preceding claims 1~~, wherein the composition comprises at least one filler selected from the group consisting of silica nanofillers, molecular silica, clay nanofillers, mica nanofillers, polymeric microfibres and glass microfibres.
14. (Currently Amended) Composition according to ~~any of the preceding claims 1~~, comprising a chain extender.
15. (Currently Amended) Composition according to ~~any of the preceding claims 1~~, wherein the number average particle size of the filler is chosen in the range of 10 to 50 000 nm, preferably 10 to 1000 nm, more preferably 10 to 500 nm.
16. (Currently Amended) Kit of parts suitable for use in an *in vivo* vessel repair, comprising a biocompatible polymer composition according to ~~any of the claims 1-15~~, and a curing-catalyst composition.
17. (Currently Amended) Kit according to claim 16, wherein the curing catalyst composition comprises at least one component selected from the group consisting of matrix pre-polymers, fillers and contrast agents.
18. (Currently Amended) Kit according to claim ~~16 or 17~~, wherein the viscosity of the curing catalyst composition is at most 1 500 cSt higher or lower than the viscosity of the biocompatible polymer composition.
19. (Currently Amended) Kit according to ~~any of the claims 16-18~~, wherein the biocompatible polymer composition mixed with the curing catalyst composition, has a curing time of 5 min or less, preferably of less than 3 min.

20. (Currently Amended) Use of a composition according to ~~any of the~~ claims 1-15, in the manufacture of a physiologically acceptable composition for the *in vivo* repair of an aneurysm, preferably an aortic aneurysm.

21. (Currently Amended) Use of a composition according to ~~any of the~~ claims 1-15, in the manufacture of a physiologically acceptable composition for prophylactic treatment of a bone, preferably a hip or a collarbone.

22. (Currently Amended) Use of a composition according to ~~any of the~~ claims 1-15, in the manufacture of a physiologically acceptable composition for securing a stent or stent-graft in an artery.

23. (Currently Amended) Cured material, obtainable by curing a composition according to ~~any of the~~ claims 1-15.


REMARKS

Prior to the calculation of the filing fee, Applicants respectfully request entry of the above preliminary amendment. The Commissioner is hereby authorized to charge any additional fees or credit overpayment to Deposit Account No. 19-0733.

Respectfully submitted,

Dated: January 2, 2004

By



John P. Iwanicki
Reg. No. 34,628
BANNER & WITCOFF, LTD.
28 State Street, 28th Floor
Boston, MA 02109
(617) 720-9600